Most recently, Sanyal et al. [16] assessed the safety and efficacy of Pegbelfermin (an FGF-21 analogue) in patients with non-alcoholic steatohepatitis, a condition commonly associated with overweight/obesity. Here, FGF21 is linked to Obesity.